STOCK TITAN

[Form 4] Neuropace, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

NeuroPace director Rakhi Kumar reported multiple acquisitions of common stock between June 2023 and June 2025, received as compensation under the company's non-employee director compensation policy in lieu of quarterly retainer fees.

Key transaction details:

  • Total shares accumulated: 15,594 shares
  • Purchase prices ranged from $4.49 to $13.20 per share
  • Largest single acquisition: 3,340 shares on June 30, 2023
  • Most recent acquisition: 1,440 shares at $10.41 on June 21, 2025

All transactions were direct acquisitions, with shares held in direct ownership. The consistent pattern of quarterly acquisitions suggests regular board compensation practices, with share quantities varying based on the prevailing stock price at each grant date.

Rakhi Kumar, direttore di NeuroPace, ha effettuato diverse acquisizioni di azioni ordinarie tra giugno 2023 e giugno 2025, ricevute come compenso secondo la politica aziendale per i direttori non dipendenti in sostituzione dei compensi trimestrali fissi.

Dettagli principali delle transazioni:

  • Numero totale di azioni accumulate: 15.594
  • Prezzi di acquisto compresi tra 4,49$ e 13,20$ per azione
  • Acquisizione singola più grande: 3.340 azioni il 30 giugno 2023
  • Acquisizione più recente: 1.440 azioni a 10,41$ il 21 giugno 2025

Tutte le transazioni sono state acquisizioni dirette, con azioni detenute in proprietà diretta. Il modello costante di acquisizioni trimestrali indica pratiche regolari di compenso del consiglio, con quantità di azioni variabili in base al prezzo di mercato alla data di assegnazione.

Rakhi Kumar, directora de NeuroPace, reportó múltiples adquisiciones de acciones comunes entre junio de 2023 y junio de 2025, recibidas como compensación bajo la política de compensación para directores no empleados de la compañía, en lugar de honorarios trimestrales fijos.

Detalles clave de las transacciones:

  • Total de acciones acumuladas: 15,594 acciones
  • Precios de compra desde $4.49 hasta $13.20 por acción
  • Mayor adquisición individual: 3,340 acciones el 30 de junio de 2023
  • Adquisición más reciente: 1,440 acciones a $10.41 el 21 de junio de 2025

Todas las transacciones fueron adquisiciones directas, con acciones en propiedad directa. El patrón constante de adquisiciones trimestrales sugiere prácticas regulares de compensación del consejo, con cantidades de acciones que varían según el precio de la acción en la fecha de concesión.

NeuroPace 이사 Rakhi Kumar는 2023년 6월부터 2025년 6월 사이에 회사의 비임원 이사 보상 정책에 따라 분기별 보수 대신 받은 보통주를 여러 차례 취득했다고 보고했습니다.

주요 거래 내역:

  • 총 누적 주식 수: 15,594
  • 주당 매입 가격 범위: $4.49~$13.20
  • 가장 큰 단일 취득: 2023년 6월 30일 3,340주
  • 가장 최근 취득: 2025년 6월 21일 $10.411,440주

모든 거래는 직접 취득으로, 주식은 직접 소유 중입니다. 분기별 꾸준한 취득 패턴은 이사회 보상 관행이 정기적임을 나타내며, 주식 수는 부여 시점의 주가에 따라 변동됩니다.

Rakhi Kumar, directrice de NeuroPace, a déclaré plusieurs acquisitions d'actions ordinaires entre juin 2023 et juin 2025, reçues en compensation selon la politique de rémunération des administrateurs non salariés de la société, en lieu et place des honoraires trimestriels.

Détails clés des transactions :

  • Total des actions accumulées : 15 594 actions
  • Prix d'achat allant de 4,49 $ à 13,20 $ par action
  • Plus grande acquisition unique : 3 340 actions le 30 juin 2023
  • Acquisition la plus récente : 1 440 actions à 10,41 $ le 21 juin 2025

Toutes les transactions étaient des acquisitions directes, avec des actions détenues en propriété directe. Le schéma constant d'acquisitions trimestrielles suggère des pratiques régulières de rémunération du conseil d'administration, les quantités d'actions variant selon le cours de l'action à la date d'attribution.

Rakhi Kumar, Direktorin von NeuroPace, meldete mehrere Erwerbe von Stammaktien zwischen Juni 2023 und Juni 2025, erhalten als Vergütung im Rahmen der Vergütungspolitik für nicht angestellte Direktoren anstelle von vierteljährlichen Pauschalhonoraren.

Wichtige Transaktionsdetails:

  • Insgesamt angesammelte Aktien: 15.594 Stück
  • Kaufpreise zwischen 4,49 $ und 13,20 $ pro Aktie
  • Größter Einzelkauf: 3.340 Aktien am 30. Juni 2023
  • Neuester Erwerb: 1.440 Aktien zu 10,41 $ am 21. Juni 2025

Alle Transaktionen waren direkte Erwerbe, bei denen die Aktien im direkten Besitz gehalten werden. Das gleichmäßige Muster der vierteljährlichen Käufe deutet auf regelmäßige Vergütungspraktiken des Vorstands hin, wobei die Anzahl der Aktien je nach aktuellem Aktienkurs zum Zeitpunkt der Zuteilung variiert.

Positive
  • None.
Negative
  • None.

Rakhi Kumar, direttore di NeuroPace, ha effettuato diverse acquisizioni di azioni ordinarie tra giugno 2023 e giugno 2025, ricevute come compenso secondo la politica aziendale per i direttori non dipendenti in sostituzione dei compensi trimestrali fissi.

Dettagli principali delle transazioni:

  • Numero totale di azioni accumulate: 15.594
  • Prezzi di acquisto compresi tra 4,49$ e 13,20$ per azione
  • Acquisizione singola più grande: 3.340 azioni il 30 giugno 2023
  • Acquisizione più recente: 1.440 azioni a 10,41$ il 21 giugno 2025

Tutte le transazioni sono state acquisizioni dirette, con azioni detenute in proprietà diretta. Il modello costante di acquisizioni trimestrali indica pratiche regolari di compenso del consiglio, con quantità di azioni variabili in base al prezzo di mercato alla data di assegnazione.

Rakhi Kumar, directora de NeuroPace, reportó múltiples adquisiciones de acciones comunes entre junio de 2023 y junio de 2025, recibidas como compensación bajo la política de compensación para directores no empleados de la compañía, en lugar de honorarios trimestrales fijos.

Detalles clave de las transacciones:

  • Total de acciones acumuladas: 15,594 acciones
  • Precios de compra desde $4.49 hasta $13.20 por acción
  • Mayor adquisición individual: 3,340 acciones el 30 de junio de 2023
  • Adquisición más reciente: 1,440 acciones a $10.41 el 21 de junio de 2025

Todas las transacciones fueron adquisiciones directas, con acciones en propiedad directa. El patrón constante de adquisiciones trimestrales sugiere prácticas regulares de compensación del consejo, con cantidades de acciones que varían según el precio de la acción en la fecha de concesión.

NeuroPace 이사 Rakhi Kumar는 2023년 6월부터 2025년 6월 사이에 회사의 비임원 이사 보상 정책에 따라 분기별 보수 대신 받은 보통주를 여러 차례 취득했다고 보고했습니다.

주요 거래 내역:

  • 총 누적 주식 수: 15,594
  • 주당 매입 가격 범위: $4.49~$13.20
  • 가장 큰 단일 취득: 2023년 6월 30일 3,340주
  • 가장 최근 취득: 2025년 6월 21일 $10.411,440주

모든 거래는 직접 취득으로, 주식은 직접 소유 중입니다. 분기별 꾸준한 취득 패턴은 이사회 보상 관행이 정기적임을 나타내며, 주식 수는 부여 시점의 주가에 따라 변동됩니다.

Rakhi Kumar, directrice de NeuroPace, a déclaré plusieurs acquisitions d'actions ordinaires entre juin 2023 et juin 2025, reçues en compensation selon la politique de rémunération des administrateurs non salariés de la société, en lieu et place des honoraires trimestriels.

Détails clés des transactions :

  • Total des actions accumulées : 15 594 actions
  • Prix d'achat allant de 4,49 $ à 13,20 $ par action
  • Plus grande acquisition unique : 3 340 actions le 30 juin 2023
  • Acquisition la plus récente : 1 440 actions à 10,41 $ le 21 juin 2025

Toutes les transactions étaient des acquisitions directes, avec des actions détenues en propriété directe. Le schéma constant d'acquisitions trimestrielles suggère des pratiques régulières de rémunération du conseil d'administration, les quantités d'actions variant selon le cours de l'action à la date d'attribution.

Rakhi Kumar, Direktorin von NeuroPace, meldete mehrere Erwerbe von Stammaktien zwischen Juni 2023 und Juni 2025, erhalten als Vergütung im Rahmen der Vergütungspolitik für nicht angestellte Direktoren anstelle von vierteljährlichen Pauschalhonoraren.

Wichtige Transaktionsdetails:

  • Insgesamt angesammelte Aktien: 15.594 Stück
  • Kaufpreise zwischen 4,49 $ und 13,20 $ pro Aktie
  • Größter Einzelkauf: 3.340 Aktien am 30. Juni 2023
  • Neuester Erwerb: 1.440 Aktien zu 10,41 $ am 21. Juni 2025

Alle Transaktionen waren direkte Erwerbe, bei denen die Aktien im direkten Besitz gehalten werden. Das gleichmäßige Muster der vierteljährlichen Käufe deutet auf regelmäßige Vergütungspraktiken des Vorstands hin, wobei die Anzahl der Aktien je nach aktuellem Aktienkurs zum Zeitpunkt der Zuteilung variiert.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kumar Rakhi

(Last) (First) (Middle)
C/O NEUROPACE, INC.
455 N. BERNARDO AVENUE

(Street)
MOUNTAIN VIEW CA 94043

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NeuroPace Inc [ NPCE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2023
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/30/2023 A 3,340(1) A $4.49 3,340 D
Common Stock 09/29/2023 A 1,541(1) A $9.73 4,881 D
Common Stock 12/29/2023 A 1,454(1) A $10.31 6,335 D
Common Stock 03/29/2024 A 1,136(1) A $13.2 7,471 D
Common Stock 06/28/2024 A 1,984(1) A $7.56 9,455 D
Common Stock 09/30/2024 A 2,152(1) A $6.97 11,607 D
Common Stock 12/21/2024 A 1,300(1) A $11.53 12,907 D
Common Stock 03/21/2025 A 1,247(1) A $12.02 14,154 D
Common Stock 06/21/2025 A 1,440(1) A $10.41 15,594 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.
/s/ Leah Akin, Attorney-in-Fact 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares of NPCE stock did Director Rakhi Kumar acquire in June 2025?

According to the Form 4 filing, Director Rakhi Kumar acquired 1,440 shares of NPCE common stock on June 21, 2025, at a price of $10.41 per share.

What is the total number of NPCE shares owned by Rakhi Kumar after the latest transaction?

Following the most recent transaction on June 21, 2025, Rakhi Kumar beneficially owned a total of 15,594 shares of NPCE common stock directly.

Why did NPCE Director Rakhi Kumar receive these shares?

According to the filing's explanation of responses, these shares were issued to Kumar pursuant to NeuroPace's non-employee director compensation policy in lieu of quarterly retainer fees.

How has the share acquisition price for NPCE Director Kumar changed over the reported period?

The share acquisition price has fluctuated significantly: starting at $4.49 in June 2023, rising to $13.20 in March 2024, dropping to $6.97 in September 2024, and most recently settling at $10.41 in June 2025.

What was the largest single acquisition of NPCE shares by Kumar during the reported period?

The largest single acquisition was 3,340 shares on June 30, 2023, at a price of $4.49 per share.
Neuropace Inc

NASDAQ:NPCE

NPCE Rankings

NPCE Latest News

NPCE Latest SEC Filings

NPCE Stock Data

330.61M
24.06M
3.38%
61.73%
0.75%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MOUNTAIN VIEW